Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

TKI cessation for CML patients with deep molecular response: an update from the...

Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France

TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial ( Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France )

Tailoring therapy for leukaemia patients

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

Tailoring therapy for leukaemia patients ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )

Updates from the EURO-SKI trial of tyrosine kinase cessation

Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France

Updates from the EURO-SKI trial of tyrosine kinase cessation ( Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France )

Incidence and risk factors for central venous catheter related thrombosis in...

Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA

Incidence and risk factors for central venous catheter related thrombosis in children ( Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA )

CML patients with stable response may safely decrease dose of TKI

Prof Mhairi Copland - University of Glasgow, Glasgow, UK

CML patients with stable response may safely decrease dose of TKI ( Prof Mhairi Copland - University of Glasgow, Glasgow, UK )

Anti CD22 CAR T cell therapy for relapsed paediatric ALL

Dr Nirali Shah - National Cancer Institute, Bethesda, USA

Anti CD22 CAR T cell therapy for relapsed paediatric ALL ( Dr Nirali Shah - National Cancer Institute, Bethesda, USA )

A new spin on leukaemia therapy

Prof Armand Keating - University of Toronto, Toronto, Canada

A new spin on leukaemia therapy ( Prof Armand Keating - University of Toronto, Toronto, Canada )

Subgroup analysis of elderly high risk AML patients receiving CPX-351

Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA

Subgroup analysis of elderly high risk AML patients receiving CPX-351 ( Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA )

Remissions following anti-CD22 CAR therapy in children with relapsed ALL

Dr Terry Fry - National Cancer Institute, Bethesda, USA

Remissions following anti-CD22 CAR therapy in children with relapsed ALL ( Dr Terry Fry - National Cancer Institute, Bethesda, USA )

CPX-351 after stem cell transplant for elderly patients with AML

Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA

CPX-351 after stem cell transplant for elderly patients with AML ( Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA )

Skull base surgery

Prof Jatin Shah - Memorial Sloan Kettering Cancer Center, New York, USA

Skull base surgery ( Prof Jatin Shah - Memorial Sloan Kettering Cancer Center, New York, USA )

Advanced oral cancer in St Petersburg

Dr Andrey Karpenko - Leningrad Regional Cancer Hospital, St Petersburg, Russia

Advanced oral cancer in St Petersburg ( Dr Andrey Karpenko - Leningrad Regional Cancer Hospital, St Petersburg, Russia )

More from ecancer